Unique technology enables unique business model

Thanks to Xspray’s unique technology to enter the market with a cheaper version of original drugs, much earlier than the generic companies can. The original companies cannot protect their products against Xspray’s versions after the expiration of the primary patents. A window of several years opens up, where Xspray becomes sole competitor on a multi billion dollar market.

Oportunities for large market shares

Xspray’s technology enables the creation of generic version of drugs lacking the “fingerprint” patented by the original companies. Because of this, the original companies aren’t able to protect the drugs after the expiration of the primary patent. Products from Xspray can be manufactured to look different, but still have the same effect and characteristics.

This opens the opportunity to enter the market as a sole competitor to the original company, long before the generic companies enter, and in a market with an annual revenue of billions of dollars.

Xspray focuses on protein kinase inhibitors, PKI:s,  and are at the verge of introducing three products to the market. Almost a fourth of all sales in cancer medicine on the market are due to PKI:s.  There are over forty PKI:s on the market and Xspray’s technique has so far been successfully tested against twenty of them, rendering the probability for success in the rest high.